Loading
Loading
Research Overview
Truncated IGF-1 variant lacking N-terminal tripeptide; reduced IGFBP binding affinity in some tissues enables more immediate IGF-1R access and localised anabolic pathway activation (PI3K/Akt/mTOR, Ras/MAPK) with shorter systemic duration than IGF-1 LR3.
Overview
IGF-1 DES is a naturally-occurring truncated variant of IGF-1, missing its first three N-terminal amino acids. This structural difference reduces its binding affinity to IGF-binding proteins (IGFBPs) in some tissue contexts, which means the compound is not sequestered by circulating binding proteins as efficiently as full-length IGF-1, enabling more immediate receptor access.
The compound's shorter half-life (approximately 30 minutes) and site-specific administration protocol position it as a research tool for studying local rather than systemic IGF-1 signalling. Research protocols typically involve injection at or near target tissue sites (commonly trained muscle groups) to investigate localised anabolic pathway activation.
IGF-1 DES is distinguished from IGF-1 LR3 (which has an extended half-life and systemic reach) by its shorter duration of action and reduced systemic exposure profile. These different pharmacokinetic characteristics make them useful for different experimental questions in IGF-1 axis research.
Compliance
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Listed as prohibited under WADA anti-doping regulations
Prescription availability in Australia and internationally
In Australia, igf-1 des (truncated igf-1) has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Audience
IGF-1 DES (Truncated IGF-1) research is most relevant to protocols examining:
Site-specific anabolic signalling and satellite cell activation research
Localised muscle repair biology studies
IGF-1 binding protein interaction comparison studies
Researchers contrasting short-acting DES vs long-acting LR3 IGF-1 variants
Protocol
Initial phase
Compound begins accumulating in target tissue. Most researchers note subtle changes by end of week one. Baseline measurements recommended.
Early response
Measurable effects begin to establish. Mid-cycle assessment is appropriate at this point in well-designed protocols.
Peak activity window
Effects compound in this window. Given limited human data, careful documentation is important.
Washout & review
Allow full washout (~5× half-life: ~30 minutes). Review data, confirm baseline recovery before any repeat protocol.
Pharmacology
Truncated IGF-1 variant lacking N-terminal tripeptide; reduced IGFBP binding affinity in some tissues enables more immediate IGF-1R access and localised anabolic pathway activation (PI3K/Akt/mTOR, Ras/MAPK) with shorter systemic duration than IGF-1 LR3.
Protocol
| Parameter | Value |
|---|---|
| Dose range | 30–150 mcg/day (site-specific) |
| Schedule | Daily, post-workout (with carbohydrate proximate) |
| Route | Subcutaneous (site-specific) |
| Half-life | ~30 minutes |
Safety
must dose with carbohydrates nearby (dose-dependent)
Support
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.